Table 1.
Current clinical trials “Recruiting” COVID‐19 patients for stem cells‐based therapies
| Trial number/identification | Condition or disease | Cell type used as an intervention | Phase |
|---|---|---|---|
| NCT04313322 | COVID‐19 | WJ‐MSCs | I |
| NCT04416139 | COVID‐19 | MSCs | II |
| NCT04336254 | COVID‐19 | Allogeneic human dental pulp stem cells | I |
| NCT04366323 | SARS‐CoV‐2 | Allogeneic and expanded adipose tissue‐derived MSCs | I/II |
| NCT04252118 | COVID‐19 | UC‐MSCs | I |
| NCT04366063 | COVID‐19 | MSCs | II, III |
| NCT04339660 | COVID‐19 | UC‐MSCs | I, II |
| NCT04392778 | COVID‐19, pneumonia, multiple organ failure | MSCs | I, II |
| NCT04355728 | COVID‐19, ARDS | UC‐MSCs | I, II |
| NCT04390139 | COVID‐19, ARDS | WJ‐MSCs | I, II |
| NCT04389450 | COVID‐19, ARDS | Allogeneic expanded placental mesenchymal‐like adherent stromal cells | II |
| NCT03042143 | ARDS | Human UC‐CD362 enriched MSCs | I/II |
| NCT04361942 | COVID‐19 pneumonia | MSCs | II |
| NCT04269525 | Viral pneumonia, ventilator‐associated | UC‐MSCs | II |
| NCT04333368 | SARS‐CoV‐2, ARDS | WJ‐MSCs | I, II |
| NCT04288102 | COVID‐19 | MSCs | II |
| ChiCTR2000030835 | Coronavirus disease 19 | WJ‐MSCs | I |
| ChiCTR2000030866 | Coronavirus disease 19 | UC‐MSCs | 0 |
| ChiCTR2000030300 | Coronavirus disease 19 infection, pulmonary fibrosis, viral pneumonia | UC‐MSCs | I |
| ChiCTR2000029990 | Coronavirus disease 19 infection, viral pneumonia | hMSCs | I/II |
| ChiCTR2000030020 | Coronavirus disease 19 infection, viral pneumonia | MSCs | II |
| ChiCTR2000029569, ChiCTR2000029572 | Coronavirus infection, pneumonia | UC‐MSCs | 0 |
| ChiCTR2000029580 | Coronavirus infection, pneumonia | MSCs | 0 |
| ChiCTR2000029606 | Coronavirus infection, pneumonia | Human menstrual blood‐derived stem cells | 0 |
| ChiCTR2000030835 | Coronavirus disease 19 infection, viral pneumonia | MSCs | NA |
| ChiCTR2000030866 | Coronavirus disease 19 infection, viral pneumonia | UC‐MSCs | 0 |
Abbreviations: ARDS, severe acute respiratory distress syndrome; COVID‐19, novel coronavirus disease; hMSC, human mesenchymal stem cell; MSC, mesenchymal stem cell; NA, not applicable; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; UC‐MSC, umbilical cord‐derived mesenchymal stem cell; WJ‐MSC, Wharton's jelly‐derived mesenchymal stem cell.